Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B-DNA
response	I-DNA
element	I-DNA
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
correlates	O
with	O
interleukin-2	B-protein
production	O
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	B-protein
molecules	I-protein
such	O
as	O
CD28	B-protein
.	O

The	O
ability	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
produce	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL-2	B-protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-DNA
response	I-DNA
element	I-DNA
(	O
CD28RE	B-DNA
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	B-DNA
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	B-DNA
kappaB	I-DNA
binding	I-DNA
motif	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	B-DNA
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	B-protein
factor	I-protein
of	I-protein
mitogenic-activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-MATp35	B-protein
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	B-protein
kappaB/Rel	I-protein
family	I-protein
members	I-protein
.	O

Induction	O
of	O
NF-MATp35	B-protein
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	B-cell_type
cells	I-cell_type
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B-protein
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF-MATp35	B-protein
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF-MATp35	B-protein
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF-MATp35	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF-MATp35	B-protein
shows	O
excellent	O
correlation	O
with	O
IL-2	B-protein
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL-2	B-protein
gene	O
expression	O
.	O

THs	NULL
JourNaL	NULL
or	NULL
BroLocicaL	NULL
CHEMISTRY	NULL
©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

14	NULL
,	NULL
Issue	NULL
of	NULL
April	NULL
5	NULL
,	NULL
pp	NULL
.	NULL

8321-8327	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Nuclear	NULL
Appearance	NULL
of	NULL
a	NULL
Factor	NULL
That	NULL
Binds	NULL
the	NULL
CD28	NULL
Response	NULL
Element	NULL
within	NULL
the	NULL
Interleukin-2	NULL
Enhancer	NULL
Correlates	NULL
with	NULL
Interleukin-2	NULL
Production*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
October	NULL
23	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
January	NULL
5	NULL
,	NULL
1996	NULL
)	NULL
Azem	NULL
Civil	NULL
}	NULL
,	NULL
Arjen	NULL
Bakker§	NULL
,	NULL
Irma	NULL
Rensink	NULL
?	NULL

,	NULL
Stefan	NULL
Lucien	NULL
A.	NULL
Aardent	NULL
,	NULL
and	NULL
Cornelis	NULL
L.Verweij	NULL
$	NULL
|	NULL
From	NULL
the	NULL
{	NULL
Central	NULL
Laboratory	NULL
of	NULL
the	NULL
Netherlands	NULL
Red	NULL
Cross	NULL
Blood	NULL
Transfusion	NULL
Service	NULL
,	NULL
Department	NULL
of	NULL
Autoimmune	NULL
Diseases	NULL
,	NULL
Amsterdam	NULL
,	NULL
1066	NULL
CX	NULL
The	NULL
Netherlands	NULL
,	NULL
the	NULL
(	NULL
Department	NULL
of	NULL
Microbiology	NULL
,	NULL
Boston	NULL
University	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02118-2394	NULL
,	NULL
and	NULL
the	NULL
§Department	NULL
of	NULL
Rheumatology	NULL
,	NULL
Academic	NULL
Hospital	NULL
Leiden	NULL
,	NULL
Leiden	NULL
,	NULL
2300	NULL
RC	NULL
The	NULL
Netherlands	NULL
Activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
requires	NULL
the	NULL
combined	NULL
signaling	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
and	NULL
costimulatory	NULL
molecules	NULL
such	NULL
as	NULL
CD28	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
produce	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
is	NULL
a	NULL
critical	NULL
control	NULL
point	NULL
in	NULL
T	NULL
lym-phocyte	NULL
activation	NULL
.	NULL

The	NULL
IL-2	NULL
enhancer	NULL
contains	NULL
a	NULL
functional	NULL
motif	NULL
named	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
that	NULL
serves	NULL
a	NULL
role	NULL
as	NULL
a	NULL
target	NULL
for	NULL
mitogenic	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

The	NULL
CD28RE	NULL
sequence	NULL
reveals	NULL
similarity	NULL
to	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
binding	NULL
motif	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
CD28RE	NULL
binds	NULL
an	NULL
inducible	NULL
protein	NULL
with	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
approximately	NULL
35	NULL
kDa	NULL
called	NULL
nuclear	NULL
factor	NULL
of	NULL
mitogenic-activated	NULL
T	NULL
cells	NULL
(	NULL
NF-MATp35	NULL
)	NULL
that	NULL
is	NULL
clearly	NULL
different	NULL
from	NULL
the	NULL
known	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
members	NULL
.	NULL

Induction	NULL
of	NULL
NF-MATp35	NULL
was	NULL
shown	NULL
to	NULL
depend	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
and	NULL
was	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
that	NULL
received	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
T	NULL
cell	NULL
stimuli	NULL
,	NULL
not	NULL
necessarily	NULL
including	NULL
CD28	NULL
signaling	NULL
.	NULL

Nonmitogenic	NULL
T	NULL
cell	NULL
stimulation	NULL
did	NULL
not	NULL
result	NULL
in	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
are	NULL
integrated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
NF-MATp35	NULL
induction	NULL
.	NULL

Similar	NULL
to	NULL
its	NULL
effect	NULL
on	NULL
IL-2	NULL
production	NULL
,	NULL
cyelosporin	NULL
A	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
NF-MATp35	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
nuclear	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
shows	NULL
excellent	NULL
correlation	NULL
with	NULL
IL-2	NULL
production	NULL
,	NULL
which	NULL
is	NULL
a	NULL
unique	NULL
characteristic	NULL
among	NULL
nuclear	NULL
factors	NULL
implicated	NULL
in	NULL
the	NULL
control	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

Proliferation	NULL
and	NULL
maturation	NULL
of	NULL
resting	NULL
T	NULL
lymphocytes	NULL
is	NULL
an	NULL
essential	NULL
process	NULL
in	NULL
the	NULL
T	NULL
cell-mediated	NULL
immune	NULL
response	NULL
.	NULL

Resting	NULL
T	NULL
lymphocytes	NULL
can	NULL
be	NULL
activated	NULL
via	NULL
noncovalent	NULL
interactions	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
complex	NULL
with	NULL
a	NULL
peptide	NULL
in	NULL
association	NULL
with	NULL
major	NULL
histocompatibility	NULL
complex	NULL
molecules	NULL
.	NULL

Besides	NULL
TCR	NULL
signaling	NULL
,	NULL
a	NULL
second	NULL
antigen-nonspecific	NULL
costimulatory	NULL
is	NULL
required	NULL
for	NULL
optimal	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
which	NULL
is	NULL
accompanied	NULL
by	NULL
the	NULL
production	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
interleukin-2	NULL
*	NULL
This	NULL
study	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Netherlands	NULL
Organization	NULL
for	NULL
Scientific	NULL
Research	NULL
and	NULL
the	NULL
Onderzoeksschool	NULL
Amsterdam-Leiden	NULL
Institute	NULL
for	NULL
Immunology	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

|	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Rheumatology	NULL
,	NULL
Academic	NULL
Hospital	NULL
Leiden	NULL
,	NULL
P.	NULL
O	NULL
.	NULL

Box	NULL
9600	NULL
,	NULL
2300	NULL
RC	NULL
Leiden	NULL
,	NULL
The	NULL
Netherlands	NULL
.	NULL

Fax	NULL
:	NULL
31-71-5266752	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin-2	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
;	NULL
NF-MAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
mitogenic	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
BrdUrd	NULL
,	NULL
Bromodeoxyuridine	NULL
.	NULL

(	NULL
IL-2	NULL
)	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

IL-2	NULL
serves	NULL
a	NULL
function	NULL
as	NULL
autocrine	NULL
growth	NULL
factor	NULL
for	NULL
T	NULL
cells	NULL
allowing	NULL
them	NULL
to	NULL
enter	NULL
the	NULL
S	NULL
phase	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Occupancy	NULL
of	NULL
the	NULL
TCR	NULL
without	NULL
a	NULL
costimulatory	NULL
signal	NULL
leads	NULL
to	NULL
aborted	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
the	NULL
development	NULL
of	NULL
functional	NULL
unresponsive-ness	NULL
or	NULL
clonal	NULL
anergy	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
T	NULL
cells	NULL
are	NULL
incapable	NULL
of	NULL
producing	NULL
IL-2	NULL
(	NULL
1	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
synthesize	NULL
IL-2	NULL
is	NULL
a	NULL
critical	NULL
control	NULL
point	NULL
in	NULL
determining	NULL
their	NULL
participation	NULL
in	NULL
an	NULL
immune	NULL
response	NULL
and	NULL
consequently	NULL
serves	NULL
as	NULL
a	NULL
model	NULL
system	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
molecular	NULL
events	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Considerable	NULL
evidence	NULL
has	NULL
indicated	NULL
that	NULL
signals	NULL
delivered	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
constitute	NULL
a	NULL
major	NULL
costimulatory	NULL
pathway	NULL
(	NULL
8	NULL
)	NULL
.	NULL

This	NULL
costimulatory	NULL
signal	NULL
is	NULL
induced	NULL
upon	NULL
interaction	NULL
of	NULL
CD28	NULL
with	NULL
its	NULL
counterreceptors	NULL
CD80	NULL
and	NULL
CD86	NULL
that	NULL
are	NULL
expressed	NULL
on	NULL
the	NULL
APC	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
directed	NULL
against	NULL
CD28	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
serve	NULL
as	NULL
a	NULL
valid	NULL
substitute	NULL
to	NULL
mimic	NULL
the	NULL
CD80-CD86	NULL
interaction	NULL
in	NULL
CD28	NULL
triggering	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Monoclonal	NULL
anti-CD28	NULL
antibodies	NULL
either	NULL
cooperate	NULL
with	NULL
soluble	NULL
anti-CD3	NULL
,	NULL
which	NULL
simulates	NULL
antigen-spe-cific	NULL
TCR	NULL
triggering	NULL
,	NULL
or	NULL
synergize	NULL
with	NULL
protein	NULL
kinase	NULL
C	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
production	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Unlike	NULL
the	NULL
TCR-induced	NULL
signaling	NULL
pathway	NULL
,	NULL
the	NULL
CD28	NULL
signal	NULL
transduction	NULL
route	NULL
does	NULL
not	NULL
involve	NULL
the	NULL
formation	NULL
of	NULL
inositol	NULL
1,4,5-trisphos-phate	NULL
or	NULL
translocation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
is	NULL
resistant	NULL
to	NULL
the	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
(	NULL
8	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
the	NULL
CD28-induced	NULL
signal	NULL
is	NULL
mediated	NULL
via	NULL
phosphatidylinositol	NULL
3-kinase	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Su	NULL
and	NULL
colleagues	NULL
(	NULL
17	NULL
)	NULL
reported	NULL
that	NULL
simultaneous	NULL
activation	NULL
of	NULL
TCR	NULL
and	NULL
CD28	NULL
results	NULL
in	NULL
a	NULL
synergistic	NULL
activation	NULL
of	NULL
c-jun	NULL
kinase	NULL
.	NULL

The	NULL
latter	NULL
observation	NULL
implies	NULL
that	NULL
TCR	NULL
and	NULL
costimulatory	NULL
signals	NULL
become	NULL
integrated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
c-jun	NULL
kinase	NULL
activation	NULL
.	NULL

Human	NULL
T	NULL
cells	NULL
respond	NULL
to	NULL
CD28	NULL
costimulation	NULL
by	NULL
a	NULL
dramatic	NULL
enhancement	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
mRNA	NULL
.	NULL

Two	NULL
mechanisms	NULL
account	NULL
for	NULL
the	NULL
CD28	NULL
co-induced	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

CD28	NULL
costimulation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
IL-2	NULL
gene	NULL
transcription	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
and	NULL
to	NULL
prolong	NULL
IL-2	NULL
mRNA	NULL
half-life	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
controlled	NULL
by	NULL
an	NULL
enhancer	NULL
extending	NULL
from	NULL
-52	NULL
to	NULL
-319	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Specific	NULL
regulatory	NULL
sequences	NULL
that	NULL
bind	NULL
the	NULL
nuclear	NULL
factors	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
NF-AT1	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
regulation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
(	NULL
re-viewed	NULL
in	NULL
Ref	NULL
.	NULL

24	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
identified	NULL
a	NULL
sequence	NULL
from	NULL
-162	NULL
to	NULL
-153	NULL
(	NULL
5'-AGAAATTCCA-3	NULL
'	NULL
)	NULL
within	NULL
the	NULL
IL-2	NULL
enhancer	NULL
that	NULL
serves	NULL
a	NULL
crucial	NULL
role	NULL
as	NULL
a	NULL
response	NULL
element	NULL
for	NULL
mitogenic	NULL
combinations	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
25	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
CD28RE	NULL
motif	NULL
is	NULL
strongly	NULL
conserved	NULL
between	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
IL-2	NULL
gene	NULL
.	NULL

Comparison	NULL
8321	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
8322	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
0	NULL
ip	NULL
=	NULL
Io	NULL
®	NULL
«	NULL
9	NULL
©	NULL
6	NULL
9g	NULL
2	NULL
a	NULL
®	NULL
-	NULL
R	NULL
PJ	NULL
a	NULL
lols	NULL
oY	NULL
oT	NULL
To	NULL
t	NULL
NF-AT	NULL
Oct	NULL
-	NULL
NF-kB	NULL
AP-1	NULL
+1	NULL
|—-	NULL
>	NULL
Transcription	NULL
~153	NULL
~151	NULL
~145	NULL
»	NULL
142	NULL
«	NULL
130	NULL
-93	NULL
-66	NULL
NF-AT	NULL
Oct	NULL
B	NULL
CD2sRe	NULL
AP	NULL
-162	NULL
-170	NULL
1	NULL
Human	NULL
IL-2	NULL
enh	NULL
.	NULL

-168	NULL
Murine	NULL
IL-2	NULL
enh	NULL
.	NULL

C	NULL
153	NULL
CD28RE	NULL
-	NULL
-	NULL
-145	NULL
15,3	NULL
15,1	NULL
1	NULL
-140	NULL
F	NULL
o	NULL
1	NULL
GGGTTTAA	NULL
AAGAGTCATCAGA	NULL
|	NULL
___	NULL
138	NULL
GGG	NULL
@	NULL
TTTAA	NULL
|AGAAATTCCA	NULL
GAGAGTCATCAGA	NULL
~162	NULL
3-	NULL
ACCTTAAAGA	NULL
-5	NULL
5-	NULL
TGGAATTTCT	NULL
-3	NULL
'	NULL
NF-KB	NULL
consensus	NULL
I_	NULL
cA	NULL
C	NULL
GGGi'éTé—ECC	NULL
-3	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
representation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
with	NULL
the	NULL
known	NULL
protein	NULL
binding	NULL
sites	NULL
(	NULL
24	NULL
,	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
location	NULL
of	NULL
these	NULL
sites	NULL
are	NULL
given	NULL
by	NULL
numbers	NULL
that	NULL
represent	NULL
the	NULL
position	NULL
in	NULL
base	NULL
pairs	NULL
relative	NULL
to	NULL
the	NULL
site	NULL
of	NULL
initiation	NULL
of	NULL
transcription	NULL
.	NULL

B	NULL
,	NULL
comparison	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
IL-2	NULL
CD28RE	NULL
sequence	NULL
.	NULL

C	NULL
,	NULL
sequence	NULL
of	NULL
CD28RE	NULL
is	NULL
compared	NULL
with	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sequence	NULL
.	NULL

of	NULL
the	NULL
sequence	NULL
with	NULL
that	NULL
of	NULL
binding	NULL
motifs	NULL
of	NULL
known	NULL
transcription	NULL
factors	NULL
reveals	NULL
similarity	NULL
to	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
motif	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Only	NULL
the	NULL
first	NULL
and	NULL
the	NULL
last	NULL
(	NULL
tenth	NULL
)	NULL
position	NULL
differ	NULL
from	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
motif	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
the	NULL
sequence	NULL
similarity	NULL
has	NULL
been	NULL
shown	NULL
by	NULL
cross	NULL
competition	NULL
studies	NULL
using	NULL
CD28RE	NULL
and	NULL
the	NULL
HIV-1	NULL
«	NULL
B	NULL
motif	NULL
in	NULL
combination	NULL
with	NULL
nuclear	NULL
extracts	NULL
of	NULL
mitogenic-activated	NULL
cells	NULL
.	NULL

The	NULL
HIV-1	NULL
kB	NULL
motif	NULL
efficiently	NULL
competed	NULL
for	NULL
CD28RE	NULL
binding	NULL
activity	NULL
,	NULL
whereas	NULL
CD28RE	NULL
proved	NULL
about	NULL
25-fold	NULL
less	NULL
effective	NULL
in	NULL
competition	NULL
for	NULL
HIV-1	NULL
«	NULL
kB	NULL
binding	NULL
activity	NULL
than	NULL
the	NULL
HIV-1	NULL
«	NULL
B	NULL
motif	NULL
itself	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
proteins	NULL
involved	NULL
in	NULL
interacting	NULL
with	NULL
CD28RE	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
binding	NULL
the	NULL
HIV-1	NULL
«	NULL
B	NULL
motif	NULL
.	NULL

In	NULL
vitro	NULL
binding	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
induction	NULL
of	NULL
CD28RE	NULL
binding	NULL
activity	NULL
is	NULL
restricted	NULL
to	NULL
T	NULL
cells	NULL
that	NULL
received	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
,	NULL
not	NULL
necessarily	NULL
including	NULL
CD28	NULL
(	NULL
25	NULL
,	NULL
28	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
characterize	NULL
the	NULL
proteins	NULL
that	NULL
constitute	NULL
the	NULL
CD28RE	NULL
binding	NULL
activity	NULL
,	NULL
we	NULL
performed	NULL
UV	NULL
cross-linking	NULL
analysis	NULL
.	NULL

In	NULL
this	NULL
manuscript	NULL
we	NULL
describe	NULL
the	NULL
characterization	NULL
of	NULL
a	NULL
protein	NULL
called	NULL
NF-MATp35	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
mitogenic	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
that	NULL
binds	NULL
CD28RE	NULL
.	NULL

Although	NULL
evidence	NULL
is	NULL
presented	NULL
that	NULL
NF-MATp35	NULL
also	NULL
binds	NULL
to	NULL
the	NULL
«	NULL
B	NULL
motif	NULL
,	NULL
NF-MATp35	NULL
is	NULL
clearly	NULL
distinct	NULL
from	NULL
the	NULL
known	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

family	NULL
members	NULL
.	NULL

It	NULL
is	NULL
demonstrated	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
NF-MATp35	NULL
shows	NULL
excellent	NULL
correlation	NULL
with	NULL
IL-2	NULL
production	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture-The	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
line	NULL
Jurkat	NULL
was	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
and	NULL
0.1	NULL
mg/ml	NULL
streptomycin	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
at	NULL
a	NULL
density	NULL
of	NULL
0.7	NULL
10°	NULL
cells/ml	NULL
as	NULL
indicated	NULL
(	NULL
monoclonal	NULL
anti-CD28	NULL
(	NULL
CLB-CD28/1	NULL
)	NULL
at	NULL
5	NULL
pg/ml	NULL
,	NULL
anti-CD3	NULL
(	NULL
CLB-T3/4.E	NULL
)	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
PMA	NULL
at	NULL
10	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
500	NULL
ng/ml	NULL
,	NULL
cyclosporin	NULL
A	NULL
at	NULL
100	NULL
ng/ml	NULL
,	NULL
and	NULL
cycloheximide	NULL
at	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

Antisera-Antibodies	NULL
for	NULL
cell	NULL
stimulation	NULL
(	NULL
CLB-CD28/1	NULL
and	NULL
CLB-T3/	NULL
4.E	NULL
)	NULL
were	NULL
from	NULL
the	NULL
CLB	NULL
in	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
.	NULL

Anti-NFxB1	NULL
(	NULL
#	NULL
sc-114	NULL
)	NULL
,	NULL
ant1-RelA	NULL
(	NULL
#	NULL
3c-109	NULL
)	NULL
,	NULL
and	NULL
anti-c-Rel	NULL
(	NULL
#	NULL
5c-71	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
California	NULL
)	NULL
.	NULL

Expression	NULL
Vectors-The	NULL
eukaryotic	NULL
expression	NULL
plasmids	NULL
that	NULL
were	NULL
used	NULL
contained	NULL
the	NULL
NFxB1l-truncated	NULL
(	NULL
at	NULL
the	NULL
Rsa-1	NULL
site	NULL
)	NULL
coding	NULL
sequence	NULL
(	NULL
pC4	NULL
KBF-Rsa	NULL
)	NULL
and	NULL
the	NULL
complete	NULL
RelA	NULL
(	NULL
pC4-65	NULL
)	NULL
and	NULL
c-Rel	NULL
(	NULL
pC4-85	NULL
)	NULL
coding	NULL
sequences	NULL
,	NULL
respectively	NULL
,	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
immediate	NULL
early	NULL
promotor	NULL
(	NULL
41	NULL
)	NULL
.	NULL

COS-7	NULL
cells	NULL
were	NULL
transfected	NULL
transiently	NULL
with	NULL
DEAE-dextran	NULL
with	NULL
either	NULL
one	NULL
the	NULL
individual	NULL
expression	NULL
vectors	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
two	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
lysis	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
buffer	NULL
containing	NULL
50	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Proteins	NULL
precipitated	NULL
from	NULL
these	NULL
extracts	NULL
with	NULL
25	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
saturated	NULL
ammo-nium	NULL
sulfate	NULL
were	NULL
resuspended	NULL
in	NULL
modified	NULL
buffer	NULL
D	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Nuclear	NULL
Extracts	NULL
and	NULL
Electromobility	NULL
Shift	NULL
Assay-Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
indicated	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Ohlsson	NULL
and	NULL
Edlund	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
finally	NULL
precipitated	NULL
with	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,50	NULL
,	NULL
(	NULL
0.3	NULL
g/m	NULL
!	NULL
)	NULL

and	NULL
dissolved	NULL
in	NULL
50	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
50	NULL
mm	NULL
KCl	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
phenyl-methylsulfony	NULL
]	NULL
fluoride	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
.	NULL

Binding	NULL
reactions	NULL
contained	NULL
6	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
,	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
about	NULL
10,000	NULL
cpm	NULL
of	NULL
a	NULL
*°P-labeled	NULL
double-stranded	NULL
probe	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
15	NULL
ul	NULL
.	NULL

Antibodies	NULL
were	NULL
added	NULL
5	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
.	NULL

As	NULL
probes	NULL
we	NULL
used	NULL
CD28RE	NULL
(	NULL
5'-gateTTTGGAATTTCTT-3	NULL
'	NULL
)	NULL
and	NULL
HIV-1	NULL
«	NULL
B	NULL
(	NULL
5	NULL
-GAGGGGACTTTCCG-3	NULL
'	NULL
)	NULL
oligonucleotides	NULL
.	NULL

Complexes	NULL
were	NULL
separated	NULL
on	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
with	NULL
45	NULL
my	NULL
Tris	NULL
borate	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
pH	NULL
8.0	NULL
buffer	NULL
.	NULL

UV	NULL
Cross-linking	NULL
and	NULL
Immunoprecipitation-Bromodeoxyuridine	NULL
(	NULL
BrdUrd	NULL
)	NULL
-substituted	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
on	NULL
a	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Millipore	NULL
Expedite	NULL
Nucleic	NULL
Acid	NULL
Synthesis	NULL
System	NULL
)	NULL
.	NULL

The	NULL
following	NULL
probes	NULL
were	NULL
used	NULL
(	NULL
thymidines	NULL
tagged	NULL
with	NULL
an	NULL
asterisk	NULL
are	NULL
substituted	NULL
by	NULL
bromodeoxyuridine	NULL
)	NULL
:	NULL
CD28RE-1	NULL
,	NULL
5'-gateAAGAAATT*CCA-AAgatc-3	NULL
'	NULL
and	NULL
3'-ctagTTCTTT*AAGGTTTctag-5	NULL
'	NULL
;	NULL
CD28RE-2	NULL
,	NULL
5'-gate-AAGAAATT*CCAAAgate-3	NULL
'	NULL
and	NULL
3	NULL
``	NULL
-ctagTTCTT*TAAGGTTTctag	NULL
5	NULL
``	NULL
;	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
8323	NULL
CD28RE-3	NULL
,	NULL
5'-gatcAAGAAATT*CCAAAgate-3	NULL
'	NULL
and	NULL
3'-ctagTTCT*T-TAAGGTTTctag	NULL
5	NULL
;	NULL
HIV-1	NULL
«	NULL
B	NULL
,	NULL
5'-gateGAGGGGACT*TTCCgate-3	NULL
'	NULL
and	NULL
3'-ctagCTCCCCT*GAAAGGctag	NULL
5	NULL
'	NULL
.	NULL

DNA	NULL
binding	NULL
reactions	NULL
were	NULL
performed	NULL
by	NULL
incubation	NULL
of	NULL
12	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
with	NULL
the	NULL
BrdUrd-substituted	NULL
probe	NULL
(	NULL
1-5	NULL
X	NULL
10	NULL
``	NULL
cpm	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
as	NULL
a	NULL
nonspecific	NULL
competitor	NULL
.	NULL

Nucleoproteins	NULL
were	NULL
first	NULL
resolved	NULL
by	NULL
gel	NULL
retardation	NULL
prior	NULL
to	NULL
UV	NULL
irradiation	NULL
in	NULL
situ	NULL
(	NULL
UV	NULL
Stratalinker	NULL
,	NULL
Stratagene	NULL
)	NULL
.	NULL

Covalently	NULL
linked	NULL
nucleoprotein	NULL
complexes	NULL
were	NULL
eluted	NULL
from	NULL
the	NULL
gel	NULL
and	NULL
further	NULL
analyzed	NULL
by	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
after	NULL
precipitation	NULL
with	NULL
acetone	NULL
.	NULL

For	NULL
immunoprecipitation	NULL
the	NULL
eluted	NULL
proteins	NULL
were	NULL
mixed	NULL
with	NULL
1	NULL
pl	NULL
of	NULL
undiluted	NULL
antiserum	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
.	NULL

The	NULL
bound	NULL
proteins	NULL
were	NULL
washed	NULL
with	NULL
radioimmune	NULL
precipitation	NULL
buffer	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
44	NULL
)	NULL
.	NULL

RESULTS	NULL
Characterization	NULL
of	NULL
CD28RE-binding	NULL
Proteins	NULL
by	NULL
UV	NULL
Cross-linking-Using	NULL
gel	NULL
retardation	NULL
analysis	NULL
,	NULL
we	NULL
and	NULL
others	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
25	NULL
,	NULL
28	NULL
)	NULL
have	NULL
demonstrated	NULL
specific	NULL
binding	NULL
of	NULL
an	NULL
inducible	NULL
nuclear	NULL
factor	NULL
with	NULL
the	NULL
CD28RE	NULL
motif	NULL
.	NULL

The	NULL
CD28RE	NULL
binding	NULL
factor	NULL
was	NULL
found	NULL
to	NULL
be	NULL
selectively	NULL
induced	NULL
by	NULL
distinct	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
stimuli	NULL
,	NULL
not	NULL
necessarily	NULL
including	NULL
CD28	NULL
signaling	NULL
(	NULL
25	NULL
,	NULL
28	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

We	NULL
named	NULL
this	NULL
factor	NULL
NF-MAT	NULL
,	NULL
which	NULL
stands	NULL
for	NULL
nuclear	NULL
factor	NULL
of	NULL
mitogenic	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
inducible	NULL
nucleoprotein	NULL
(	NULL
s	NULL
)	NULL
that	NULL
constitutes	NULL
NF-MAT	NULL
,	NULL
we	NULL
performed	NULL
UV	NULL
cross-linking	NULL
experiments	NULL
with	NULL
a	NULL
5'-bromo-2'-deoxyuridine-substituted	NULL
CD28RE	NULL
probe	NULL
.	NULL

Nuclear	NULL
extract	NULL
of	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
was	NULL
incubated	NULL
with	NULL
this	NULL
probe	NULL
,	NULL
and	NULL
the	NULL
protein-bound	NULL
DNA	NULL
fraction	NULL
was	NULL
separated	NULL
by	NULL
gel	NULL
retardation	NULL
and	NULL
subjected	NULL
to	NULL
in	NULL
situ	NULL
UV	NULL
irradiation	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
cross-linked	NULL
protein-DNA	NULL
complexes	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
two	NULL
protein-DNA	NULL
bands	NULL
that	NULL
migrated	NULL
with	NULL
molecular	NULL
masses	NULL
of	NULL
35	NULL
and	NULL
70	NULL
kDa	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Next	NULL
we	NULL
applied	NULL
UV	NULL
cross-linking	NULL
analysis	NULL
to	NULL
confirm	NULL
that	NULL
the	NULL
CD28RE-protein	NULL
complex	NULL
that	NULL
appeared	NULL
upon	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
via	NULL
different	NULL
modes	NULL
of	NULL
mitogenic	NULL
T	NULL
cell	NULL
activation	NULL
revealed	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
protein-DNA	NULL
bands	NULL
as	NULL
we	NULL
observed	NULL
for	NULL
the	NULL
complex	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
CD28RE-binding	NULL
proteins	NULL
selectively	NULL
showed	NULL
up	NULL
in	NULL
nuclei	NULL
of	NULL
mitogenic	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
refer	NULL
to	NULL
the	NULL
proteins	NULL
that	NULL
correspond	NULL
to	NULL
the	NULL
35-	NULL
and	NULL
70-kDa	NULL
cross-linked	NULL
adducts	NULL
as	NULL
NF-MATp35	NULL
and	NULL
NF-MATp7O	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
actual	NULL
molecular	NULL
mass	NULL
of	NULL
these	NULL
proteins	NULL
could	NULL
be	NULL
slightly	NULL
lower	NULL
than	NULL
that	NULL
of	NULL
the	NULL
respective	NULL
protein-DNA	NULL
complexes	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
covalently	NULL
bound	NULL
oligonucleotide	NULL
.	NULL

NF-MATp35	NULL
May	NULL
Bind	NULL
CD28RE	NULL
as	NULL
a	NULL
Dimer-Many	NULL
nuclear	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
their	NULL
cognate	NULL
binding	NULL
motif	NULL
as	NULL
a	NULL
dimer	NULL
(	NULL
26	NULL
,	NULL
27	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Both	NULL
homo-	NULL
and	NULL
heterodimers	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
DNA	NULL
binding	NULL
.	NULL

To	NULL
explore	NULL
the	NULL
possibility	NULL
that	NULL
NF-MATp7O0	NULL
represents	NULL
the	NULL
dimeric	NULL
form	NULL
of	NULL
NF-MATp35	NULL
,	NULL
we	NULL
performed	NULL
UV	NULL
dose	NULL
titration	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
revealed	NULL
that	NULL
upon	NULL
short	NULL
exposure	NULL
(	NULL
F.e	NULL
.	NULL

1	NULL
min	NULL
)	NULL
the	NULL
35-kDa	NULL
band	NULL
predominated	NULL
,	NULL
whereas	NULL
the	NULL
balance	NULL
shifted	NULL
toward	NULL
the	NULL
70-kDa	NULL
band	NULL
during	NULL
long	NULL
exposure	NULL
(	NULL
15	NULL
min	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
the	NULL
protein	NULL
present	NULL
in	NULL
the	NULL
70-kDa	NULL
complex	NULL
represents	NULL
the	NULL
homodimer	NULL
of	NULL
the	NULL
35-kDa	NULL
protein	NULL
moiety	NULL
.	NULL

NF-MATp35	NULL
Is	NULL
Distinct	NULL
from	NULL
the	NULL
Known	NULL
NF-	NULL
«	NULL
B/Rel	NULL
Family	NULL
Members-The	NULL
CD28RE	NULL
sequence	NULL
revealed	NULL
similarity	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
(	NULL
18	NULL
,	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
kB	NULL
motifs	NULL
to	NULL
compete	NULL
for	NULL
NF-MAT	NULL
binding	NULL
,	NULL
we	NULL
determined	NULL
whether	NULL
NF-	NULL
«	NULL
B	NULL
immunoreactivity	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
UV	NULL
cross-linked	NULL
CD28RE-protein	NULL
complex	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

44	NULL
it	NULL
is	NULL
demonstrated	NULL
that	NULL
none	NULL
of	NULL
the	NULL
antibodies	NULL
directed	NULL
against	NULL
the	NULL
individual	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
NFxB1	NULL
,	NULL
Rel-A	NULL
,	NULL
and	NULL
c-Rel	NULL
were	NULL
able	NULL
to	NULL
immunoprecipitate	NULL
CD28RE	NULL
cross-linked	NULL
protein	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
these	NULL
antibodies	NULL
to	NULL
immunoprecipitate	NULL
NF-	NULL
«	NULL
B/Rel-DNA	NULL
complexes	NULL
was	NULL
demonstrated	NULL
using	NULL
recombinant	NULL
NF-	NULL
«	NULL
B/Rel	NULL
A	NULL
«	NULL
-CD3	NULL
«	NULL
-CD28	NULL
PMA	NULL
Ionomycin	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
«	NULL
-CD3	NULL
«	NULL
-CD28	NULL
PMA	NULL
Ionomycin	NULL
Mw	NULL
(	NULL
kDa	NULL
)	NULL
--	NULL
-	NULL
_	NULL
106	NULL
_-	NULL
80	NULL
ne-mat	NULL
pro	NULL
-	NULL
>	NULL
-	NULL
Suk	NULL
M	NULL
_-	NULL
49,5	NULL
NF-MAT	NULL
p35	NULL
|	NULL
--	NULL
*	NULL
“	NULL
J	NULL
--	NULL
32,5	NULL
_-	NULL
27,5	NULL
sites	NULL
-	NULL
(	NULL
+	NULL
>	NULL
1	NULL
2	NULL
3	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Characterization	NULL
of	NULL
CD28RE-binding	NULL
proteins	NULL
.	NULL

A	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
CD28RE	NULL
as	NULL
probe	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
free	NULL
probe	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
nonstimulated	NULL
Jurkat	NULL
cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

B	NULL
,	NULL
UV	NULL
cross-linking	NULL
analysis	NULL
of	NULL
CD28RE-binding	NULL
proteins	NULL
.	NULL

The	NULL
probe	NULL
used	NULL
was	NULL
BrdUrd-substituted	NULL
CD28RE-1	NULL
.	NULL

Lane	NULL
I	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Molecular	NULL
mass	NULL
(	NULL
Mw	NULL
)	NULL
markers	NULL
are	NULL
shown	NULL
on	NULL
the	NULL
side	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
BrdUrd-substituted	NULL
CD28RE-2	NULL
and	NULL
CD28RE-3	NULL
probes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

proteins	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
BrdUrd-incorporated	NULL
HIV-1	NULL
«	NULL
B	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Evidence	NULL
for	NULL
Binding	NULL
of	NULL
NF-MATp35	NULL
to	NULL
the	NULL
HIV-1	NULL
NF-kB	NULL
Motif-NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
are	NULL
known	NULL
to	NULL
be	NULL
efficiently	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
receiving	NULL
a	NULL
single	NULL
stimulus	NULL
.	NULL

In	NULL
analogy	NULL
with	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
8324	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
Time	NULL
{	NULL
min	NULL
)	NULL
:	NULL
0	NULL
1	NULL
2.55	NULL
7.5	NULL
10	NULL
15	NULL
Mw	NULL
(	NULL
kDa	NULL
)	NULL
-	NULL
106	NULL
NF-MAT	NULL
p70	NULL
=	NULL
--	NULL
-P	NULL
go	NULL
--	NULL
49,5	NULL
NFMATp3S	NULL
-p	NULL
o	NULL
'	NULL
.	NULL

’	NULL
-	NULL
...	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
UV	NULL
irradiation	NULL
for	NULL
cross-linking	NULL
nucleoproteins	NULL
to	NULL
BrdUrd-substituted	NULL
CD28RE-1	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
plus	NULL
anti-CD3	NULL
was	NULL
incubated	NULL
with	NULL
BrdUrd-substituted	NULL
CD28RE-1	NULL
and	NULL
subjected	NULL
to	NULL
gel	NULL
retardation	NULL
.	NULL

Nucleoprotein-DNA	NULL
complexes	NULL
were	NULL
UV	NULL
irradiated	NULL
for	NULL
the	NULL
time	NULL
indicated	NULL
and	NULL
analyzed	NULL
by	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

these	NULL
observations	NULL
,	NULL
anti-CD3	NULL
or	NULL
PMA	NULL
alone	NULL
proved	NULL
to	NULL
be	NULL
effective	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
HIV-1	NULL
«	NULL
B	NULL
motif	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

When	NULL
HIV-1	NULL
«	NULL
B	NULL
protein	NULL
complexes	NULL
formed	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
cells	NULL
that	NULL
received	NULL
a	NULL
single	NULL
stimulus	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
stimuli	NULL
,	NULL
we	NULL
observed	NULL
both	NULL
quantitative	NULL
and	NULL
qualitative	NULL
differences	NULL
.	NULL

Complexes	NULL
that	NULL
appeared	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
cells	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
stimuli	NULL
revealed	NULL
increased	NULL
intensity	NULL
and	NULL
were	NULL
extended	NULL
with	NULL
a	NULL
form	NULL
exhibiting	NULL
enhanced	NULL
mobility	NULL
(	NULL
C2	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
NF-MATp35	NULL
contributes	NULL
to	NULL
the	NULL
HIV-1	NULL
NF-	NULL
«	NULL
B-protein	NULL
complex	NULL
,	NULL
we	NULL
performed	NULL
UV	NULL
cross-linking	NULL
experiments	NULL
with	NULL
a	NULL
BrdUrd-incorporated	NULL
HIV-1	NULL
«	NULL
B	NULL
motif	NULL
.	NULL

With	NULL
nuclear	NULL
extracts	NULL
of	NULL
nonmitogenic	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
two	NULL
major	NULL
protein-DNA	NULL
bands	NULL
with	NULL
molecular	NULL
masses	NULL
of	NULL
approximately	NULL
70-85	NULL
kDa	NULL
and	NULL
50	NULL
kDa	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

HIV-1	NULL
«	NULL
B-protein	NULL
complexes	NULL
that	NULL
were	NULL
formed	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
cells	NULL
that	NULL
have	NULL
received	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
activation	NULL
signals	NULL
contained	NULL
an	NULL
additional	NULL
protein-DNA	NULL
product	NULL
with	NULL
a	NULL
molecular	NULL
mass	NULL
identical	NULL
to	NULL
that	NULL
of	NULL
the	NULL
NF-MATp35-CD28RE	NULL
complex	NULL
.	NULL

Distinct	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
conditions	NULL
led	NULL
to	NULL
the	NULL
inclusion	NULL
of	NULL
this	NULL
protein	NULL
in	NULL
the	NULL
HIV-1	NULL
«	NULL
B-protein	NULL
complex	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
NF-MATp35-CD28RE	NULL
complex	NULL
,	NULL
the	NULL
35-kDa	NULL
protein-HIV-1	NULL
«	NULL
B	NULL
complex	NULL
could	NULL
not	NULL
be	NULL
immunoprecipitated	NULL
with	NULL
anti-NFB1	NULL
,	NULL
anti-RelA	NULL
,	NULL
and	NULL
anti-c-Rel	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
NF-MATp35	NULL
Is	NULL
Dependent	NULL
on	NULL
de	NULL
Novo	NULL
Protein	NULL
Synthesis-To	NULL
determine	NULL
whether	NULL
nuclear	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
is	NULL
dependent	NULL
on	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
on	NULL
the	NULL
mitogen-inducible	NULL
nuclear	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
cycloheximide	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
reduction	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
NF-MAT	NULL
binding	NULL
to	NULL
CD28RE	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
either	NULL
NF-MATp35	NULL
itself	NULL
must	NULL
be	NULL
synthesized	NULL
or	NULL
that	NULL
another	NULL
protein	NULL
needs	NULL
to	NULL
be	NULL
synthesized	NULL
that	NULL
activates	NULL
a	NULL
pre-existing	NULL
but	NULL
inactive	NULL
form	NULL
of	NULL
NF-MATp35	NULL
.	NULL

When	NULL
the	NULL
HIV-1	NULL
xB	NULL
motif	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
cycloheximide	NULL
selectively	NULL
inhibited	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
fast	NULL
migrating	NULL
moiety	NULL
(	NULL
C2	NULL
)	NULL
of	NULL
the	NULL
mitogenic	NULL
induced	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-serum	NULL
directed	NULL
against	NULL
NFxB1	NULL
reveals	NULL
that	NULL
the	NULL
complex	NULL
that	NULL
appears	NULL
with	NULL
extracts	NULL
of	NULL
nuclei	NULL
from	NULL
mitogenic	NULL
stimulated	NULL
(	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
)	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
A	NULL
a	NULL
«	NULL
-NFKBI	NULL
ci-RelA	NULL
a-cRe	NULL
!	NULL

c-IL8	NULL
Mw	NULL
(	NULL
kDa	NULL
)	NULL
__	NULL
106	NULL
--	NULL
80	NULL
NE-MATp7O	NULL
«	NULL
-p	NULL
--	NULL
49,5	NULL
NF-MATp35	NULL
.-p	NULL
__	NULL
32,5	NULL
__	NULL
27.5	NULL
--	NULL
18,5	NULL
1	NULL
.	NULL

3	NULL
is	NULL
4	NULL
G	NULL
cx-CD03/CD28	NULL
CD28RE	NULL
B	NULL
«	NULL
-NFKBL	NULL
oncRel	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
c-IL8	NULL
--	NULL
106	NULL
c-Rel	NULL
--	NULL
»	NULL
RelA	NULL
-+	NULL
-	NULL
so	NULL
NFKB1	NULL
--	NULL
»	NULL
--	NULL
49,5	NULL
--	NULL
82,5	NULL
-_	NULL
27,5	NULL
717	NULL
2	NULL
3s	NULL
4	NULL
5	NULL
6	NULL
7	NULL
a	NULL
I	NULL
NFKB1/c-Rel	NULL
NFKB1/ReIA	NULL
HIV-1	NULL
kB	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
UV	NULL
cross-linked	NULL
CD2SRE-1-NF-MAT	NULL
.	NULL

A	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-induced	NULL
NF-MAT	NULL
was	NULL
UV	NULL
cross-linked	NULL
with	NULL
BrdUrd-substituted	NULL
CD28RE-1	NULL
.	NULL

Immunoprecipitations	NULL
of	NULL
UV	NULL
cross-linked	NULL
NF-MATp35	NULL
and	NULL
NF-MATp70	NULL
were	NULL
performed	NULL
with	NULL
anti-NF-xB/Re	NULL
!	NULL

antibodies	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
without	NULL
antibodies	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
with	NULL
anti-IL8	NULL
as	NULL
negative	NULL
control	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
with	NULL
anti-NFxB1	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
with	NULL
anti-RelA	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
with	NULL
anti-c-Rel	NULL
.	NULL

B	NULL
,	NULL
immunoprecipitation	NULL
of	NULL
BrdUrd-substituted	NULL
HIV-1	NULL
«	NULL
kB	NULL
UV	NULL
cross-linked	NULL
NF-	NULL
«	NULL
b/Re	NULL
!	NULL

l	NULL
proteins	NULL
.	NULL

Recombinant	NULL
NFxB1/c-Rel	NULL
(	NULL
anes	NULL
1-5	NULL
)	NULL
and	NULL
NF	NULL
«	NULL
B1/Re	NULL
!	NULL

A	NULL
(	NULL
Zanes	NULL
6-9	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
by	NULL
anti-NF-xB/Re	NULL
!	NULL

antibodies	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
6	NULL
,	NULL
without	NULL
antibodies	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
,	NULL
with	NULL
anti-NFxB1	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
,	NULL
with	NULL
anti-RelA	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
,	NULL
with	NULL
anti-c-Rel	NULL
;	NULL
lane	NULL
6	NULL
with	NULL
anti-IL-8	NULL
as	NULL
a	NULL
control	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
8325	NULL
«	NULL
-CD3	NULL
-	NULL
|	NULL
-f-	NULL
|-	NULL
]	NULL
-	NULL
]	NULL
+	NULL
}	NULL
+	NULL
]	NULL
+	NULL
«	NULL
-CD28	NULL
-	NULL
-	NULL
|	NULL
-	NULL
+	NULL
]	NULL
+l	NULL
~	NULL
l+	NULL
l+	NULL
PMA	NULL
-	NULL
-	NULL
|	NULL
+	NULL
-	NULL
l+	NULL
l+	NULL
ot	NULL
-	NULL
s*	NULL
C2	NULL
--	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
s	NULL
9	NULL
a-CD3	NULL
«	NULL
CD28	NULL
PMA	NULL
cHx	NULL
Mwi	NULL
(	NULL
kDa	NULL
)	NULL
-	NULL
106	NULL
-	NULL
--	NULL
80	NULL
__	NULL
-	NULL
49,5	NULL
_-	NULL
-	NULL
32,5	NULL
_-	NULL
-	NULL
27,5	NULL
sill	NULL
--	NULL
18,5	NULL
1	NULL
.	NULL

2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
&	NULL
.g	NULL
.	NULL

$	NULL
349	NULL
“	NULL
HIVA1	NULL
kB	NULL
es	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Characterization	NULL
of	NULL
HIV-1	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
induction	NULL
of	NULL
HIV-1	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
end-labeled	NULL
HIV-1	NULL
«	NULL
B	NULL
oligonucleotide	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
for	NULL
8	NULL
h.	NULL
Lane	NULL
1	NULL
,	NULL
free	NULL
probe	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
nuclear	NULL
extract	NULL
of	NULL
unstimulated	NULL
cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
nuclear	NULL
extract	NULL
of	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
;	NULL
Zane	NULL
4	NULL
,	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
anti-CD28	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
anti-CD8	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
PMA	NULL
plus	NULL
anti-CD3	NULL
plus	NULL
anti	NULL
CD28	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
.	NULL

B	NULL
,	NULL
UV	NULL
cross-linking	NULL
of	NULL
HIV-1	NULL
«	NULL
B-binding	NULL
proteins	NULL
.	NULL

The	NULL
probes	NULL
used	NULL
were	NULL
the	NULL
BrdUrd-substituted	NULL
CD28RE-1	NULL
(	NULL
Fane	NULL
1	NULL
)	NULL
and	NULL
HIV-1	NULL
kB	NULL
sequence	NULL
(	NULL
Zanes	NULL
2-7	NULL
)	NULL
.	NULL

Lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
6	NULL
,	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
with	NULL
anti-CD38	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
with	NULL
PMA	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
plus	NULL
cycloheximide	NULL
.	NULL

cycloheximide	NULL
resembles	NULL
the	NULL
complex	NULL
induced	NULL
upon	NULL
nonmitogenic	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

UV	NULL
cross-linking	NULL
analysis	NULL
with	NULL
a	NULL
BrdUrd-substituted	NULL
HIV-1	NULL
xB	NULL
motif	NULL
shows	NULL
that	NULL
the	NULL
complex	NULL
that	NULL
appears	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
is	NULL
devoid	NULL
of	NULL
the	NULL
p35	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
NF-MAT	NULL
data	NULL
and	NULL
substanti-	NULL
«	NULL
-CD3	NULL
«	NULL
-CD28	NULL
PMA	NULL
CHX	NULL
CsA	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
CD28RE	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Influence	NULL
of	NULL
cycloheximide	NULL
and	NULL
CsA	NULL
on	NULL
the	NULL
appearance	NULL
of	NULL
NF-MAT	NULL
.	NULL

Gel	NULL
retardation	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
CD28RE	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
was	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
cycloheximide	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
Zanes	NULL
5-7	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
,	NULL
anti-CD8	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
,	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
7	NULL
,	NULL
anti-CD28	NULL
plus	NULL
PMA	NULL
.	NULL

ates	NULL
the	NULL
conclusion	NULL
that	NULL
the	NULL
protein	NULL
that	NULL
constitutes	NULL
the	NULL
35-kDa	NULL
protein-HIV-1	NULL
«	NULL
B	NULL
complex	NULL
is	NULL
identical	NULL
to	NULL
NF-MATp35	NULL
.	NULL

Effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
Nuclear	NULL
Appearance	NULL
of	NULL
NF-MATp35-Next	NULL
we	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NF-MATp35	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
we	NULL
monitored	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
appearance	NULL
of	NULL
NF-MAT/CD28RE	NULL
complex	NULL
formation	NULL
.	NULL

CsA	NULL
prevented	NULL
NF-MAT	NULL
induction	NULL
after	NULL
treatment	NULL
with	NULL
anti-CD3	NULL
in	NULL
combination	NULL
of	NULL
either	NULL
anti-CD28	NULL
or	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
response	NULL
of	NULL
NF-MAT	NULL
to	NULL
the	NULL
stimuli	NULL
that	NULL
included	NULL
Ca**	NULL
signaling	NULL
was	NULL
inhibited	NULL
by	NULL
CsA	NULL
,	NULL
the	NULL
response	NULL
to	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
CD28	NULL
,	NULL
a	NULL
Ca**-independent	NULL
mode	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
CsA	NULL
.	NULL

This	NULL
result	NULL
is	NULL
in	NULL
favor	NULL
of	NULL
the	NULL
conclusion	NULL
that	NULL
distinct	NULL
combinations	NULL
of	NULL
signaling	NULL
pathways	NULL
converge	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-MAT	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NF-MAT	NULL
are	NULL
in	NULL
perfect	NULL
correlation	NULL
with	NULL
the	NULL
effects	NULL
of	NULL
CsA	NULL
on	NULL
IL-2	NULL
production	NULL
.	NULL

As	NULL
anticipated	NULL
we	NULL
found	NULL
a	NULL
similar	NULL
effect	NULL
with	NULL
CsA	NULL
on	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
fast	NULL
migrating	NULL
moiety	NULL
(	NULL
C2	NULL
)	NULL
of	NULL
the	NULL
HIV-1	NULL
«	NULL
B-protein	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

This	NULL
result	NULL
further	NULL
substantiates	NULL
the	NULL
conclusion	NULL
that	NULL
this	NULL
moiety	NULL
represents	NULL
the	NULL
NF-MATp35	NULL
containing	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
we	NULL
describe	NULL
an	NULL
approximately	NULL
35-kDa	NULL
inducible	NULL
protein	NULL
,	NULL
named	NULL
NF-MATp35	NULL
,	NULL
which	NULL
interacts	NULL
with	NULL
the	NULL
CD28RE	NULL
within	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

Distinct	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
contribute	NULL
to	NULL
the	NULL
nuclear	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
,	NULL
indicating	NULL
that	NULL
there	NULL
is	NULL
a	NULL
redundancy	NULL
in	NULL
the	NULL
activation	NULL
requirements	NULL
of	NULL
NF-MATp35	NULL
.	NULL

We	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
CD28RE	NULL
sequence	NULL
displays	NULL
similarity	NULL
with	NULL
the	NULL
«	NULL
kB	NULL
enhancer	NULL
consensus	NULL
motif	NULL
.	NULL

The	NULL
Rel-related	NULL
proteins	NULL
c-Rel	NULL
,	NULL
NFxB1	NULL
,	NULL
and	NULL
RelA	NULL
constitute	NULL
a	NULL
major	NULL
class	NULL
of	NULL
xB	NULL
enhancer-binding	NULL
proteins	NULL
.	NULL

In	NULL
line	NULL
with	NULL
this	NULL
Ghosh	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
8326	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
e-CD3	NULL
a-CD28	NULL
PMA	NULL
CHX	NULL
CsA	NULL
C1	NULL
--	NULL
»	NULL
C2	NULL
--	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
s	NULL
6	NULL
7	NULL
HIV-1	NULL
kB	NULL
«	NULL
-CD3	NULL
«	NULL
-CD28	NULL
CHX	NULL
«	NULL
-NFKB1	NULL
0.0	NULL
'	NULL
it	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7-7	NULL
5	NULL
HIVA	NULL
kB	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Influence	NULL
of	NULL
cycloheximide	NULL
and	NULL
CsA	NULL
on	NULL
the	NULL
appearance	NULL
of	NULL
mitogenic	NULL
induced	NULL
HIV-1	NULL
xB	NULL
binding	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
gel	NULL
retardation	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
HIV-1	NULL
«	NULL
B	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
was	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Fane	NULL
1	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
cycloheximide	NULL
(	NULL
anes	NULL
2-4	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
Zanes	NULL
5-7	NULL
)	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
plus	NULL
PMA	NULL
;	NULL
Zanes	NULL
2	NULL
and	NULL
5	NULL
,	NULL
anti-CD3	NULL
plus	NULL
TaBtE	NULL
I	NULL
Summary	NULL
of	NULL
requirements	NULL
for	NULL
induction	NULL
of	NULL
IL-2	NULL
production	NULL
and	NULL
nuclear	NULL
expression	NULL
of	NULL
NF-MAT	NULL
Stimulus	NULL
IL-2	NULL
NF-MAT	NULL
aCD8/aCD28	NULL
+	NULL
+	NULL
aCD8/aCD28/CsA	NULL
-	NULL
aCD28/PMA	NULL
+	NULL
+	NULL
aCD28/PMA/CsA	NULL
+	NULL
+	NULL
aCD3/PMA	NULL
+	NULL
+	NULL
aCD3/PMA/CsA	NULL
-	NULL
PMA	NULL
-	NULL
aCD3	NULL
-	NULL
aCD28	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
were	NULL
able	NULL
to	NULL
detect	NULL
the	NULL
presence	NULL
of	NULL
NF	NULL
«	NULL
B1	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
c-Rel	NULL
among	NULL
the	NULL
proteins	NULL
that	NULL
bind	NULL
CD28RE	NULL
.	NULL

However	NULL
,	NULL
the	NULL
affinity	NULL
for	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
is	NULL
low	NULL
as	NULL
judged	NULL
from	NULL
competition	NULL
experiments	NULL
and	NULL
UV	NULL
cross-linking	NULL
studies	NULL
performed	NULL
by	NULL
us	NULL
and	NULL
others	NULL
(	NULL
19	NULL
,	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
clearly	NULL
demonstrate	NULL
that	NULL
NF-MATp35	NULL
is	NULL
distinct	NULL
from	NULL
NFkB1	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
c-Rel	NULL
.	NULL

First	NULL
,	NULL
the	NULL
activation	NULL
requirements	NULL
of	NULL
NF-MATp35	NULL
are	NULL
more	NULL
stringent	NULL
than	NULL
those	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
members	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
NF-MATp35	NULL
does	NULL
not	NULL
match	NULL
those	NULL
of	NULL
the	NULL
individual	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

proteins	NULL
.	NULL

Third	NULL
,	NULL
antibodies	NULL
directed	NULL
against	NULL
NFxB1	NULL
,	NULL
RelA	NULL
,	NULL
or	NULL
c-Rel	NULL
have	NULL
not	NULL
been	NULL
successful	NULL
in	NULL
immunopre-cipitating	NULL
NF-MATp35	NULL
covalently	NULL
linked	NULL
to	NULL
CD28RE	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
is	NULL
dependent	NULL
on	NULL
protein	NULL
synthe-sis	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
Fraser	NULL
and	NULL
Weiss	NULL
(	NULL
30	NULL
)	NULL
reported	NULL
that	NULL
the	NULL
predominant	NULL
protein	NULL
species	NULL
present	NULL
in	NULL
the	NULL
CD28RC	NULL
constitute	NULL
three	NULL
proteins	NULL
of	NULL
35	NULL
,	NULL
36	NULL
,	NULL
and	NULL
44	NULL
kDa	NULL
.	NULL

The	NULL
most	NULL
abundant	NULL
were	NULL
the	NULL
35/36-kDa	NULL
proteins	NULL
.	NULL

It	NULL
could	NULL
be	NULL
that	NULL
NF-MATp35	NULL
is	NULL
related	NULL
to	NULL
one	NULL
of	NULL
these	NULL
proteins	NULL
;	NULL
however	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
NF-MATp35	NULL
,	NULL
the	NULL
CD28RC	NULL
proteins	NULL
require	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
CD28	NULL
signaling	NULL
for	NULL
their	NULL
nuclear	NULL
appearance	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
none	NULL
of	NULL
these	NULL
proteins	NULL
appears	NULL
upon	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
plus	NULL
PMA	NULL
but	NULL
requires	NULL
the	NULL
addition	NULL
of	NULL
a	NULL
third	NULL
stimulus	NULL
,	NULL
i.e	NULL
.	NULL

ionomycin	NULL
.	NULL

Furthermore	NULL
,	NULL
Li	NULL
and	NULL
Siekevitz	NULL
(	NULL
31	NULL
)	NULL
described	NULL
a	NULL
45-kDa	NULL
Tax	NULL
inducible	NULL
protein	NULL
(	NULL
TxREF	NULL
)	NULL
distinct	NULL
from	NULL
NF-	NULL
«	NULL
B/Rel	NULL
that	NULL
specifically	NULL
interacts	NULL
with	NULL
CD28RE	NULL
.	NULL

This	NULL
protein	NULL
could	NULL
be	NULL
related	NULL
to	NULL
the	NULL
44-kDa	NULL
protein	NULL
described	NULL
by	NULL
Fraser	NULL
and	NULL
Weiss	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
low	NULL
affinity	NULL
of	NULL
CD28RE	NULL
for	NULL
binding	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

proteins	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
differences	NULL
in	NULL
the	NULL
5	NULL
and	NULL
3	NULL
'	NULL
extremities	NULL
between	NULL
CD28RE	NULL
and	NULL
NF-	NULL
«	NULL
B/Rel	NULL
binding	NULL
motifs	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
various	NULL
NF-	NULL
«	NULL
B/Rel	NULL
binding	NULL
motifs	NULL
has	NULL
showed	NULL
that	NULL
the	NULL
5	NULL
and	NULL
3	NULL
'	NULL
ends	NULL
of	NULL
the	NULL
recognition	NULL
motif	NULL
are	NULL
the	NULL
best	NULL
conserved	NULL
parts	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
crystallographic	NULL
analysis	NULL
of	NULL
NF-	NULL
«	NULL
B-DNA	NULL
complexes	NULL
,	NULL
it	NULL
is	NULL
believed	NULL
that	NULL
these	NULL
parts	NULL
of	NULL
the	NULL
«	NULL
B	NULL
binding	NULL
motif	NULL
in	NULL
particular	NULL
are	NULL
involved	NULL
in	NULL
NF-	NULL
«	NULL
B/Rel	NULL
binding	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
NF-MATp35	NULL
binds	NULL
to	NULL
the	NULL
«	NULL
B	NULL
elements	NULL
as	NULL
well	NULL
as	NULL
to	NULL
CD28RE	NULL
,	NULL
whereas	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
have	NULL
a	NULL
preference	NULL
for	NULL
the	NULL
consensus-matching	NULL
sequences	NULL
,	NULL
indicates	NULL
that	NULL
less	NULL
variation	NULL
is	NULL
tolerated	NULL
for	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
than	NULL
for	NULL
NF-MATp35	NULL
.	NULL

This	NULL
might	NULL
implicate	NULL
that	NULL
every	NULL
«	NULL
B	NULL
element	NULL
is	NULL
in	NULL
potency	NULL
able	NULL
to	NULL
bind	NULL
NF-MATp35	NULL
.	NULL

A	NULL
functional	NULL
role	NULL
of	NULL
CD28RE	NULL
as	NULL
a	NULL
mitogen	NULL
response	NULL
element	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
stems	NULL
from	NULL
studies	NULL
wherein	NULL
a	NULL
mutant	NULL
enhancer	NULL
with	NULL
a	NULL
nonfunctional	NULL
CD28RE	NULL
site	NULL
anti-CD28	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
,	NULL
anti-CD8	NULL
plus	NULL
PMA	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
7	NULL
,	NULL
anti-CD28	NULL
plus	NULL
PMA	NULL
.	NULL

B	NULL
,	NULL
gel	NULL
retardation	NULL
assay	NULL
was	NULL
performed	NULL
with	NULL
HIV-1	NULL
xB	NULL
as	NULL
probe	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
anes	NULL
1-4	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
(	NULL
Zanes	NULL
5-8	NULL
)	NULL
of	NULL
antibodies	NULL
directed	NULL
against	NULL
NF	NULL
«	NULL
B1	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
5	NULL
,	NULL
cells	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
anti-CD3	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
,	NULL
anti-CD3	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
,	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Identification	NULL
of	NULL
NF-MAT	NULL
8327	NULL
was	NULL
used	NULL
in	NULL
transient	NULL
expression	NULL
studies	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
the	NULL
requirements	NULL
for	NULL
NF-MATp35	NULL
induction	NULL
,	NULL
mutations	NULL
within	NULL
the	NULL
CD28RE	NULL
motif	NULL
affected	NULL
the	NULL
IL-2	NULL
enhancer	NULL
in	NULL
its	NULL
capacity	NULL
to	NULL
respond	NULL
to	NULL
mitogenic	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

Because	NULL
CD28RE	NULL
serves	NULL
a	NULL
role	NULL
as	NULL
a	NULL
response	NULL
element	NULL
for	NULL
distinct	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
not	NULL
necessarily	NULL
including	NULL
CD28	NULL
signaling	NULL
,	NULL
we	NULL
propose	NULL
to	NULL
name	NULL
the	NULL
element	NULL
MARS	NULL
,	NULL
which	NULL
stands	NULL
for	NULL
mitogenic	NULL
activation	NULL
responsive	NULL
sequence	NULL
(	NULL
35	NULL
)	NULL
.	NULL

IL-2	NULL
production	NULL
is	NULL
either	NULL
completely	NULL
resistant	NULL
(	NULL
anti-CD28	NULL
plus	NULL
PMA	NULL
)	NULL
or	NULL
sensitive	NULL
(	NULL
anti-CD3	NULL
plus	NULL
either	NULL
anti-CD28	NULL
or	NULL
PMA	NULL
)	NULL
to	NULL
the	NULL
immunosuppressive	NULL
action	NULL
of	NULL
CsA	NULL
(	NULL
13	NULL
,	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
by	NULL
CsA	NULL
is	NULL
explained	NULL
by	NULL
the	NULL
negative	NULL
effects	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
nuclear	NULL
expression	NULL
of	NULL
the	NULL
cyto-plasmic	NULL
component	NULL
of	NULL
NF-AT	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
Oct-1/AP1	NULL
,	NULL
both	NULL
known	NULL
to	NULL
be	NULL
TCR-responsive	NULL
nuclear	NULL
proteins	NULL
(	NULL
37-40	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
demonstrated	NULL
that	NULL
nuclear	NULL
appearance	NULL
of	NULL
NF-MATp35	NULL
is	NULL
also	NULL
sensitive	NULL
to	NULL
CsA	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
NF-MATp35	NULL
for	NULL
CsA	NULL
is	NULL
,	NULL
similar	NULL
to	NULL
IL-2	NULL
gene	NULL
expression	NULL
,	NULL
dependent	NULL
on	NULL
the	NULL
mode	NULL
of	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

When	NULL
Ca**	NULL
influx	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
signaling	NULL
regime	NULL
,	NULL
NF-MAT	NULL
still	NULL
appears	NULL
.	NULL

Taken	NULL
together	NULL
the	NULL
above	NULL
mentioned	NULL
results	NULL
show	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
NF-MATp35	NULL
reveals	NULL
excellent	NULL
correlation	NULL
with	NULL
activation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

This	NULL
is	NULL
a	NULL
unique	NULL
characteristic	NULL
among	NULL
nuclear	NULL
proteins	NULL
implicated	NULL
in	NULL
IL-2	NULL
gene	NULL
regulation	NULL
and	NULL
suggests	NULL
a	NULL
crucial	NULL
role	NULL
for	NULL
NF-MATp35	NULL
in	NULL
IL-2	NULL
gene	NULL
regulation	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
NF-MATp35	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
c-jun	NULL
kinase	NULL
revealed	NULL
excellent	NULL
correlation	NULL
with	NULL
IL-2	NULL
production	NULL
(	NULL
17	NULL
)	NULL
.	NULL

However	NULL
,	NULL
based	NULL
on	NULL
supershift	NULL
analysis	NULL
and	NULL
immunoprecipitation	NULL
experiments	NULL
with	NULL
anti-c-jun	NULL
antibodies	NULL
,	NULL
we	NULL
could	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
NF-MATp35	NULL
is	NULL
identical	NULL
to	NULL
c-jun	NULL
.	NULL
``	NULL

c-jun	NULL
kinase	NULL
is	NULL
the	NULL
only	NULL
protein	NULL
kinase	NULL
among	NULL
the	NULL
kinases	NULL
involved	NULL
in	NULL
mitogenic	NULL
signaling	NULL
described	NULL
so	NULL
far	NULL
that	NULL
requires	NULL
mitogenic	NULL
combinations	NULL
of	NULL
T	NULL
cell	NULL
stimuli	NULL
for	NULL
its	NULL
activation	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
signal	NULL
integration	NULL
occurs	NULL
at	NULL
an	NULL
even	NULL
more	NULL
prox-imal	NULL
step	NULL
in	NULL
the	NULL
events	NULL
that	NULL
lead	NULL
to	NULL
IL-2	NULL
gene	NULL
transcription	NULL
than	NULL
NF-MATp35	NULL
induction	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
investigate	NULL
whether	NULL
NF-MATp35	NULL
is	NULL
somehow	NULL
involved	NULL
in	NULL
c-jun	NULL
kinase	NULL
signaling	NULL
.	NULL

REFERENCES	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1349-1356	NULL
.	NULL

Springer	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
846	NULL
,	NULL
425-4834	NULL
.	NULL

Weaver	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
and	NULL
Unanue	NULL
,	NULL
E.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
49-54	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
240	NULL
,	NULL
1169-1176	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Science	NULL
224	NULL
,	NULL
1812-1814	NULL
.	NULL

Beverly	NULL
,	NULL
B.	NULL
,	NULL
Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

4	NULL
,	NULL
661-671	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
355-361	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
211-216	NULL
@	NULL
Oum	NULL
to	NULL
bo	NULL
1	NULL
go	NULL
=i	NULL
2	NULL
A	NULL
.	NULL

Civil	NULL
,	NULL
A.	NULL
Bakker	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

9	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
5031-5034	NULL
10	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Bleustone	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
321-331	NULL
11	NULL
.	NULL

Hansen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
Nowinski	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1980	NULL
)	NULL
Immunogenetics	NULL
10	NULL
,	NULL
247-260	NULL
12	NULL
.	NULL

Van	NULL
Lier	NULL
,	NULL
R.	NULL
A.	NULL
W.	NULL
,	NULL
Brouwer	NULL
,	NULL
M.	NULL
,	NULL
de	NULL
Jong	NULL
,	NULL
R.	NULL
,	NULL
Groot	NULL
,	NULL
M.	NULL
,	NULL
de	NULL
Groot	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Leucocyte	NULL
Typing	NULL
(	NULL
Knapp	NULL
,	NULL
W.	NULL
,	NULL
Dorken	NULL
,	NULL
B.	NULL
,	NULL
Gilks	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
Rieber	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Schmidt	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Stein	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Von	NULL
dem	NULL
Borne	NULL
,	NULL
A.	NULL
E.	NULL
G.	NULL
,	NULL
eds	NULL
)	NULL
Vol	NULL
.	NULL

IV	NULL
,	NULL
pp	NULL
.	NULL

353-355	NULL
,	NULL
Oxford	NULL
University	NULL
Press	NULL
,	NULL
Oxford	NULL
.	NULL

13	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gillespie	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
4472-4481	NULL
14	NULL
.	NULL

Ward	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Westick	NULL
,	NULL
J.	NULL
,	NULL
Hall	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
and	NULL
Sansom	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
2572-2577	NULL
15	NULL
.	NULL

Pages	NULL
,	NULL
F.	NULL
,	NULL
Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Rattapel	NULL
,	NULL
R.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Nunes	NULL
,	NULL
J.	NULL
,	NULL
Imbert	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Olive	NULL
,	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
369	NULL
,	NULL
327-330	NULL
16	NULL
.	NULL

Rudd	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Janssen	NULL
,	NULL
O.	NULL
,	NULL
Ca	NULL
,	NULL
Y.-C.	NULL
,	NULL
da	NULL
Silva	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Raab	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Prasad	NULL
,	NULL
K.	NULL
V.	NULL
(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
225-234	NULL
17	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
,	NULL
Jacinto	NULL
,	NULL
E.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Kallunki	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ben-Neriah	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
77	NULL
,	NULL
727-136	NULL
18	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
19	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Geerts	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
14179-14182	NULL
20	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
339-348	NULL
21	NULL
.	NULL

Umlauf	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Lantz	NULL
,	NULL
0	NULL
and	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
3197-3205	NULL
22	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Morgan	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
395-407	NULL
23	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shibuya	NULL
,	NULL
H	NULL
,	NULL
Ohashi	NULL
,	NULL
T.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
401-407	NULL
24	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Loh	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
333-342	NULL
25	NULL
.	NULL

Civil	NULL
,	NULL
A.	NULL
,	NULL
Geerts	NULL
,	NULL
M.	NULL
,	NULL
Aarden	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Kur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
3041-3043	NULL
26	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Henkel	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
27	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Brown	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
,	NULL
405-455	NULL
28	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
1696-1700	NULL
29	NULL
.	NULL

Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Struct	NULL
.	NULL

Biol	NULL
.	NULL

1	NULL
,	NULL
71-79	NULL
30	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992b	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
4357-4363	NULL
31	NULL
.	NULL

Li	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Siekevitz	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
6490-6500	NULL
32	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4412-4421	NULL
33	NULL
.	NULL

Ghosh	NULL
,	NULL
G.	NULL
,	NULL
Van	NULL
Duyne	NULL
,	NULL
G.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Sigler	NULL
,	NULL
P.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
378	NULL
,	NULL
303-310	NULL
34	NULL
.	NULL

Muller	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Rey	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
Sodeoka	NULL
,	NULL
M.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
and	NULL
Harrison	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
311-317	NULL
85	NULL
.	NULL

Civil	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

146	NULL
,	NULL
158-164	NULL
36	NULL
.	NULL

Bloemena	NULL
,	NULL
E.	NULL
,	NULL
Van	NULL
Oers	NULL
,	NULL
R.	NULL
H.	NULL
J.	NULL
,	NULL
Weinreich	NULL
(	NULL
1989	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

19	NULL
,	NULL
943-946	NULL
37	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
38	NULL
.	NULL

Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
352	NULL
,	NULL
803-807	NULL
39	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Soderling	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
3747-3752	NULL
40	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
274-281	NULL
41	NULL
.	NULL

Boshart	NULL
,	NULL
M.	NULL
,	NULL
Weber	NULL
,	NULL
F.	NULL
,	NULL
Jahn	NULL
,	NULL
G.	NULL
,	NULL
Dorsch-Hasler	NULL
,	NULL
K.	NULL
,	NULL
Fleckenstein	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
41	NULL
,	NULL
521-530	NULL
42	NULL
.	NULL

Dignam	NULL
,	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1484	NULL
43	NULL
.	NULL

Ohlsson	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Edlund	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
45	NULL
,	NULL
35-44	NULL
44	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Walker	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Sista	NULL
,	NULL
P.	NULL
,	NULL
Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Dixon	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Hannink	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
63	NULL
,	NULL
803-814	NULL
45	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
46	NULL
.	NULL

Garrity	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
D.	NULL
,	NULL
Rothenberg	NULL
,	NULL
E.	NULL
V.	NULL
,	NULL
and	NULL
Wold	NULL
,	NULL
B.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cel	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
2159-2169	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Nuclear	NULL
Appearance	NULL
of	NULL
a	NULL
Factor	NULL
That	NULL
Binds	NULL
the	NULL
CD28	NULL
Response	NULL
Element	NULL
within	NULL
the	NULL
Interleukin-2	NULL
Enhancer	NULL
Correlates	NULL
with	NULL
Interleukin-2	NULL
Production	NULL
Azem	NULL
Civil	NULL
,	NULL
Arjen	NULL
Bakker	NULL
,	NULL
Irma	NULL
Rensink	NULL
,	NULL
Stefan	NULL
Doerre	NULL
,	NULL
Lucien	NULL
A.	NULL
Aarden	NULL
and	NULL
Cornelis	NULL
L.	NULL
Verwey	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:8321-8327.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.14.8321	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/14/8321	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
references	NULL
,	NULL
18	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
4/8321	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

